{
    "type": "ETP",
    "ucits": false,
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": "Leverage, Synthetic replication via swaps, Counterparty risk, Daily reset compounding effect, Structured product features",
    "classification": "complex",
    "supporting_data": "The product is a GraniteShares 3x Long AstraZeneca Daily ETP, which seeks to replicate 3 times the daily performance of AstraZeneca PLC via the Solactive Daily Leveraged 3x Long AstraZeneca PLC Index. It uses a swap with Natixis as the swap provider, indicating synthetic replication. The product employs significant leverage (3x daily leverage) with a daily reset, causing a compounding effect that makes returns over periods longer than one day deviate from the simple leveraged multiple of the underlying asset. The swap introduces counterparty risk, mitigated by collateral held at an independent custodian, but still a risk factor. The product is an Exchange Traded Product (ETP), not a UCITS ETF, and is explicitly described as complex and high risk (risk class 7/7). The structure involves derivatives integral to the investment objective, leverage beyond UCITS limits, and synthetic replication, all of which under MiFID II Article 254 and Delegated Regulation EU 2017/565 Article 57 criteria classify it as complex. The productu2019s payoff and risk profile are difficult for retail investors with basic knowledge to understand, requiring an appropriateness assessment. The PRIIPs KID includes a comprehension alert stating the product is not simple and may be difficult to understand. These factors confirm the complex classification under MiFID II rules."
}